Abstract:270 Background: Radiotracers used in prostate-specific membrane antigen (PSMA) positron emission tomography (PET) imaging have high specificity for the detection of prostate cancer (PCa), and PSMA PET/CT imaging has seen increased use in the management of localized PCa. However, the diagnostic capability of PSMA PET can be limited by intense uptake in the ureters, bladder, and urethra due to physiologic urinary excretion. Specifically, radiotracer activity in the prostatic urethra can be misinterpreted as a midline intraprostatic lesion if not carefully evaluated with morphologic imaging. This study aimed to elucidate the correlation between positive 18 F-DCFPyL activity in the midline prostate with hyperintense signal on T2-weighted MRI (T2W MRI) within the prostatic urethra as an indication of retained urine. Methods: Ninety-seven patients received both 18 F-DCFPyL PSMA PET/CT and 3 Tesla prostate MRI post-void imaging for localized, high-risk PCa. Patients with prior prostate treatment (i.e., surgery, androgen deprivation therapy, or radiotherapy) or poor prostatic urethra visualization (i.e., PCa involving the whole gland, Foley catheter in situ) were excluded, resulting in a final cohort of 84 patients. Radiotracer activity in the midline region of the prostate was prospectively evaluated by two nuclear medicine physicians during PET/CT read outs. Post-void T2W MRI scans were retrospectively evaluated for the presence of residual urine noted as hyperintensity within the prostatic urethral lumen by one genitourinary radiologist blinded to PET/CT evaluations. The corresponding prostatic urethra diameters were measured on both axial and sagittal T2W MRI. Fisher’s exact test and Mann-Whitney U tests were used to compare MRI and PET/CT findings. Results: In 84 patients, midline activity on PSMA PET imaging was documented in 16 patients (the case group), whereas the remaining 68 patients without midline activity constituted the control group. In total, 75% (12/16) and 31% (21/68) of patients in the case and control groups, respectively, had urethral hyperintensity on T2W MRI (p < .01, Fisher’s exact test). In patients with a hyperintense urethral lumen at MRI, there was a significant difference in mean prostatic urethral measurements between the case and control groups in both axial (7.25 mm vs. 2.81 mm, p < .0001, Mann Whitney U) and sagittal (12.25 mm vs. 5.43 mm, p < .0001, Mann Whitney U) planes. Conclusions: Our findings suggest that PSMA uptake within the midline of the prostate is more commonly observed in patients with a prominently visible prostatic urethra at MRI, a finding that is likely associated with the stagnation of urine containing PSMA tracer. This midline uptake may be prone to misinterpretation as a potential PCa lesion on PSMA PET/CT, and the use of post-void MRIs may be useful in reducing the likelihood of false positive interpretations of PSMA PET/CT.

Increased Prostate-Specific Membrane Antigen Uptake in a Gallbladder Stone

Unusual Prostate-Specific Membrane Antigen (PSMA) Splenic Uptake in a Patient With Prostate Cancer

An exploratory study of unexplained concentration of 18F-PSMA-1007 in the bladder for prostate cancer PET/CT imaging

Distinguishing Physiological Ureter Uptake From an Involved Lymph Node in Staging Prostate-Specific Membrane Antigen (PSMA) Scans: Implications for Radiation Planning

Prostate-Specific Membrane Antigen Uptake Heterogeneity in Mixed Ductal-Acinar Adenocarcinoma of the Prostate

Peritumoral/vascular Expression of PSMA As a Diagnostic Marker in Hepatic Lesions

Intense 18F-PSMA-1007 Uptake of Splenic Hemangioma

Unsuspected Isolated Peritoneal Metastasis of Prostate Cancer Detected with Digital F-18 PSMA PET/CT Scan

Optimal Time Point for 68Ga-PSMA-11 PET/CT Imaging in the Assessment of Suspected Metastatic Prostate Cancer in the Bladder of Postprostatectomy Patient

Intrahepatic cholangiocarcinoma detected on 18F-PSMA-1007 PET/MR imaging in a prostate cancer patient: a case report and literature review

68Ga-PSMA-11 PET Identified Tumor Recurrence in Prostatectomy Bed With Rising PSA of 0.9 ng/mL but Negative on MRI and 18F-Fluciclovine PET Scan

Incidental Finding of Spindle Cell Sarcoma on 68Ga-PSMA-11 PET/CT

An 18F-MD-PSMA (Multi-Dentate PMSA Imaging Agent) PET/CT in Prostate Cancer Relapse: Results of a Retrospective Trial.

Detection of benign granular cell tumor of the breast via 18F-PSMA-PET/CT in a patient with very high-risk prostate cancer: A case report

Case Report: 18F-PSMA-1007 PET/CT Avid Solitary Penile Metastasis of Castration-Resistant Prostate Cancer With a PSA of 0.072 ng/ml

An Albumin-Binding PSMA Ligand with Higher Tumor Accumulation for PET Imaging of Prostate Cancer

Preclinical Evaluation and Pilot Clinical Study of Al18F-PSMA-BCH for Prostate Cancer PET Imaging.

64Cu-PSMA-BCH: a new radiotracer for delayed PET imaging of prostate cancer

Elevated 99mTc-MDP and 18F-NaF Uptake in a Bladder Stone.

PSMA PET imaging for evaluation of recurrent or persistent prostate cancer after primary prostate radiation.

Effect of urinary stagnation in the prostatic urethra on generating false-positive midline lesions on 18 F-DCFPyL PSMA PET/CT.